Resultados de Búsqueda

NICE

NICE

When prostate cancer no longer responds to hormone treatment (androgen deprivation therapy), but has not spread beyond the prostate, the only option was to continue androgen deprivation therapy. Darolutamide added to androgen deprivation therapy would be another option at this stage. Clinical trial evidence shows that people taking darolutamide with androgen deprivation therapy have longer metastasis-free survival and overall survival compared with androgen deprivation therapy alone. However, ...

NICE

NICE

Treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma depends on where it starts. If it starts in the oral cavity (mouth), it is usually first treated with cetuximab combination therapy (cetuximab with platinum and 5‑fluorouracil [5-FU] chemotherapy). If it starts outside the oral cavity it is treated with chemotherapy (platinum and 5-FU) alone. Clinical trial evidence from people who have head and neck squamous cell carcinoma that expresses a biomarker ...

NICE

NICE

NICE guidance recommends both pomalidomide plus dexamethasone and panobinostat plus bortezomib and dexamethasone after 3 previous lines of treatment for relapsed and refractory multiple myeloma. Panobinostat plus bortezomib was not considered in the comparison due to its toxic effects and lack of efficacy. A clinical trial demonstrated that the use of isatuximab together with pomalidomide and dexamethasone extended the progression-free survival compared to the use of pomalidomide and ...

NICE

NICE

Carfilzomib can be effective at late stages of the disease and does not appear to be associated with neuropathic adverse reactions to the same extent as standard treatment. It also offers a longer remission time. The company presented data from 2 clinical trials: carfilzomib plus dexamethasone, compared with bortezomib plus dexamethasone and carfilzomib plus lenalidomide and dexamethasone, compared with lenalidomide plus dexamethasone. The committee concluded the trial evidence showed a ...

NICE

NICE

Evidence-based recommendations. Carfilzomib is a possible treatment for multiple myeloma in adults who have had only 1 previous therapy.